Exercise on GLP-1 Medication: Why Movement Matters (and Why People Get It Wrong at the Start)
If you’ve recently started GLP-1 medication (such as semaglutide or tirzepatide), exercise can suddenly feel confusing.
Some people feel pressure to exercise more to “make the most” of GLP-1 medication for weight loss.
Others feel unexpectedly tired, weak, or flat and stop exercising altogether.
Many people swing between the two.
Neither response means you’re doing anything wrong.
It usually means no one has explained how exercise fits into GLP-1 treatment, especially in the early stages.
This article explains:
why exercise matters on GLP-1 medication
why fatigue and weakness are common at the start
common exercise mistakes on GLP-1 medication
how movement supports energy and muscle, not just weight loss
This is not a workout plan. It’s an explanation of what’s happening so you can make informed decisions.
What people expect from GLP-1 medication vs what actually happens
Most people start GLP-1 medication expecting one main change: reduced appetite.
That often happens quickly.
What’s less expected is that energy, strength, and physical confidence don’t improve at the same pace. Appetite is regulated hormonally. Fitness is maintained through use.
When appetite drops but routines change too fast, people often think:
“I’m eating less, so why do I feel more tired?”
“Exercise feels harder than it should.”
“Am I losing muscle?”
“Is GLP-1 medication not working properly for me?”
These questions are understandable - but they’re usually pointing to adaptation, not failure.
Appetite changes faster than physical capacity
GLP-1 receptor agonists reduce hunger and food preoccupation by acting on the brain–gut axis.
Muscle strength, cardiovascular fitness and stamina work differently. They are dependent on use.
When appetite decreases, many people:
eat less without intending to
move less because they feel low energy
rest more to cope with fatigue
Over time, this combination can lead to deconditioning.
What deconditioning feels like on GLP-1 Medication
lower baseline energy
feeling drained after everyday tasks
exercise tolerance dropping
less trust in your body
This is often misattributed to the medication itself, when it’s actually a predictable response to reduced intake and reduced movement happening together.
Why exercise on GLP-1 medication isn’t about weight loss
In diet culture, exercise is framed as a way to burn calories or accelerate fat loss.
On GLP-1 medication, this framing causes problems.
Early on, exercise primarily supports:
muscle preservation
circulation and digestion
energy regulation
mood stability
confidence in physical ability
These benefits occur regardless of weight change.
Trying to use exercise to “speed things up” often leads to:
post-exercise nausea
delayed fatigue
irritability or low mood
reduced consistency
Exercise works best on GLP-1 medication when it supports function, not optimisation.
Why over-exercising can make symptoms worse
One of the most confusing experiences people report on GLP-1 medication is this:
“I exercised and felt fine… and then hours later I felt awful.”
This delay is important.
During exercise, adrenaline and other stress hormones temporarily mask fatigue, nausea, and low energy availability. You can feel capable in the moment, even if your system doesn’t have the resources to recover well afterwards.
Later that day, or sometimes the next day, people notice:
nausea that wasn’t present before
dizziness or light-headedness
heavy fatigue that feels out of proportion
irritability, low mood, or emotional flatness
Because the response is delayed, it’s easy to miss the connection. People often blame the medication, their sleep, or themselves.
What’s usually happening is a mismatch between output and recovery.
GLP-1 medications can reduce hunger cues that would normally prompt you to refuel or rest. That doesn’t mean your body doesn’t need fuel or recovery. It just means the signals are quieter.
Early on, this creates a situation where it’s very easy to do more than your current intake and energy availability can support.
This doesn’t mean exercise is unsafe.
It means pacing matters more than people expect.
The problem with “making the most of the meds”
Many people approach GLP-1 medication with a sense of urgency.
There’s a feeling that this is a limited opportunity and that they should:
exercise more
be more disciplined
finally “do it properly”
This mindset is understandable, especially for people who have spent years trying to manage their weight through effort and control.
The problem is that urgency increases risk.
When appetite drops suddenly, people often assume their body is more resilient than it is. In reality, it’s adapting to a new hormonal environment while also receiving less energy.
Pushing exercise harder during this phase can:
increase stress hormone output
worsen fatigue
disrupt sleep
reduce consistency altogether
The irony is that this approach often slows progress, not because exercise is bad, but because recovery hasn’t caught up.
Why walking is one of the best exercises on GLP-1 Medication
Walking is often dismissed because it doesn’t feel impressive.
That’s precisely why it works during periods of physiological change.
From a physical perspective, walking:
places lower demand on energy reserves
supports circulation without large stress spikes
encourages digestion and bowel motility
is less likely to provoke delayed nausea
From a behavioural perspective, walking:
requires minimal planning
creates less decision fatigue
is easier to repeat daily
builds confidence rather than testing limits
Consistency matters more than intensity when appetite, energy, and routines are shifting.
Ten minutes most days sends a very different message to the body than forty minutes once or twice a week followed by several days of exhaustion.
It says: movement is still part of my life.
The psychological impact of exercise changes on GLP-1 medication
Exercise isn’t just a physical behaviour. It’s tied closely to identity, self-trust, and self-worth.
When movement suddenly feels harder, many people internalise it.
They think:
“I should be fitter than this.”
“I’m being lazy.”
“I’m wasting this opportunity.”
This self-criticism matters.
Psychological stress increases cortisol and sympathetic nervous system activation, both of which can worsen fatigue and disrupt appetite regulation. In other words, judging yourself for struggling often makes the struggle worse.
Early on, movement that builds confidence and predictability is far more supportive than movement that challenges limits or feeds self-criticism.
Feeling capable matters.
Why stopping exercise completely can backfire
At the other end of the spectrum, some people stop exercising altogether.
This often happens because they feel:
unusually tired
unsure what’s safe
worried about nausea or dizziness
Short periods of rest can be appropriate. Prolonged withdrawal from movement tends to have unintended consequences.
Reduced movement can contribute to:
stiffness and joint discomfort
lower mood
worsening fatigue
anxiety about restarting
The body adapts to inactivity surprisingly quickly. When people later try to resume movement, it often feels harder than expected, reinforcing the belief that something is “wrong”.
This can create a loop:
reduced movement → lower confidence → more avoidance → further deconditioning.
Gentle, consistent movement helps interrupt this pattern.
Exercise, muscle mass, and long-term health on GLP-1 medication
As GLP-1 medications become more widely used, there’s increasing attention on lean mass preservation during weight loss.
Muscle plays a central role in:
metabolic health
balance and injury prevention
physical independence
long-term weight maintenance
Weight loss without adequate muscle preservation can lead to:
weakness
reduced functional capacity
higher risk of regain later
Exercise sends a signal to the body that muscle is still needed.
Early on, that signal doesn’t need to be intense or complex. It needs to be regular.
Even light, repeated movement contributes to muscle retention when paired with adequate nourishment over time.
Why motivation is unreliable on GLP-1 Medication
Many people notice changes in motivation, pleasure, or drive on GLP-1 medication.
This isn’t a personal failing. GLP-1 medication affects reward pathways in the brain as well as appetite.
Relying on motivation to exercise is unreliable.
What works better is structure.
From an occupational perspective, behaviours are more likely to stick when they:
are planned in advance
require minimal decision-making
fit into existing routines
Movement that is predictable and low friction is easier to maintain when internal cues are changing.
This is why people often do better with “same time, same thing” approaches early on.
Common exercise mistakes on GLP-1 medication
These patterns are very common early on:
Exercising to compensate for eating less
This recreates diet-culture dynamics and increases fatigue risk.
Waiting until you “feel like it”
Motivation cues are often blunted.
Stopping movement entirely
This can worsen energy and confidence over time.
Comparing yourself to pre-GLP-1 medication fitness
Your body is in a different context now.
None of these mean you’re failing. They mean expectations need adjusting.
A better question to ask about exercise on GLP-1 medication
Instead of asking:
“How hard should I push?”
Try asking:
“What helps my body feel capable tomorrow?”
This question shifts exercise away from punishment and optimisation, and toward support and sustainability.
Movement that leaves you feeling steadier, clearer, or more grounded is doing its job.
Movement that leaves you depleted, anxious, or unwell is not.
Why this phase is temporary
For most people, the early GLP-1 medication adjustment phase settles as:
eating becomes more consistent
energy stabilises
routines adapt
Exercise options naturally expand later.
Early restraint isn’t giving up. It’s pacing.
What to take from this
Exercise on GLP-1 isn’t about doing more.
It’s about doing enough to support your body while it adapts.
Understanding this reduces anxiety, self-blame, and unnecessary trial-and-error.
Practical implementation comes later, once the foundation is stable.
For now, clarity is the work.
References
Bellicha, A., van Baak, M.A., Battista, F., Beaulieu, K., Blundell, J.E., Busetto, L., Carraça, E.V., Dicker, D., Encantado, J., Ermolao, A. and Farpour-Lambert, N. (2021) ‘Effect of exercise training on weight loss, body composition and cardiometabolic health during energy restriction: a systematic review and meta-analysis’, Obesity Reviews, 22(2), e13151. https://doi.org/10.1111/obr.13151
Binmahfoz, A., Alotaibi, M., Alzahrani, S., Alharbi, A. and Alshehri, M. (2025) ‘Effect of resistance exercise on body composition, muscle strength and cardiometabolic markers during weight loss: a systematic review’, BMJ Open Sport & Exercise Medicine, 11(1), e001679. https://doi.org/10.1136/bmjsem-2024-001679
Bull, F.C., Al-Ansari, S.S., Biddle, S., Borodulin, K., Buman, M.P., Cardon, G., Carty, C., Chaput, J.P., Chastin, S., Chou, R. and Dempsey, P.C. (2020) ‘World Health Organization 2020 guidelines on physical activity and sedentary behaviour’, British Journal of Sports Medicine, 54(24), pp. 1451–1462. https://doi.org/10.1136/bjsports-2020-102955
Cava, E., Yeat, N.C. and Mittendorfer, B. (2017) ‘Preserving healthy muscle during weight loss’, Advances in Nutrition, 8(3), pp. 511–519. https://doi.org/10.3945/an.116.014506
Ceasovschih, A., Hancu, N. and Roman, G. (2025) ‘Glucagon-like peptide-1 receptor agonists and skeletal muscle: effects on body composition, mechanisms, and mitigation strategies’, Current Opinion in Endocrinology, Diabetes and Obesity, 32(2), pp. 92–99. https://doi.org/10.1097/MED.0000000000000910
Codella, R., Luzi, L. and Terruzzi, I. (2025) ‘GLP-1 receptor agonists and exercise: implications for lifestyle intervention and muscle preservation’, Frontiers in Endocrinology, 16, 1382219. https://doi.org/10.3389/fendo.2025.1382219
Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M.C. and Stefanski, A. (2022) ‘Tirzepatide once weekly for the treatment of obesity’, The New England Journal of Medicine, 387(3), pp. 205–216. https://doi.org/10.1056/NEJMoa2206038
Jayedi, A., Soltani, S., Zargar, M.S., Khan, T.A. and Shab-Bidar, S. (2024) ‘Dose–response association of aerobic physical activity with weight loss in adults: a systematic review and meta-analysis of randomised controlled trials’, JAMA Network Open, 7(1), e2351899. https://doi.org/10.1001/jamanetworkopen.2023.51899
Look, M., Ryan, D.H., Astrup, A., Wilding, J.P.H. and Rubino, D. (2025) ‘Body composition changes during weight reduction with tirzepatide: a post hoc analysis of the SURMOUNT-1 trial’, Diabetes, Obesity and Metabolism, 27(3), pp. 602–610. https://doi.org/10.1111/dom.15221
Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M., Rosenstock, J., Tran, M.T.D., Wadden, T.A. and Wharton, S. (2021) ‘Once-weekly semaglutide in adults with overweight or obesity’, The New England Journal of Medicine, 384(11), pp. 989–1002. https://doi.org/10.1056/NEJMoa2032183
Wilding, J.P.H., Batterham, R.L., Davies, M., Van Gaal, L.F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B.M., Rosenstock, J., Rubino, D. and Wadden, T.A. (2021) ‘Changes in body composition with semaglutide 2.4 mg in adults with overweight or obesity: exploratory analyses of the STEP 1 trial’, Diabetes, Obesity and Metabolism, 23(8), pp. 1913–1923. https://doi.org/10.1111/dom.14419
World Health Organization (2020) WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization.
